In multiple myeloma, the pro-tumoral effect of IL-18 was shown to be due of its release in a NLRP3-dependent from TAMs [150] and favored the immunosuppressive activity of MDSCs [149]. The gene discussed is IL18; the disease is plasma cell myeloma.